Abstract
Atrial fibrillation (AF) is a common cardiac arrhythmia leading to many adverse outcomes and increased mortality. Yet the molecular mechanisms underlying AF remain largely unknown. Recent advances in high-throughput technologies make large-scale molecular profiling possible. In the past decade, multiomics studies of AF have identified a number of potential biomarkers of AF. In this review, we focus on the studies of multiomics profiles with AF risk. We summarize recent advances in the discovery of novel biomarkers for AF through multiomics studies. We also discuss limitations and future directions in risk assessment and discovery of therapeutic targets for AF.
Funding Information
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • European Union’s Horizon 2020 Research and Innovation Programme (838259)
  • American Heart Association (18SFRN34150007)
  • American College of Cardiology Foundation
  • Merck Research Fellowship in Cardiovascular Diseases and Cardiometabolic Disorders
  • National Institutes of Health (5R01HL128914)
  • National Institutes of Health (2R01 HL092577)
  • National Institutes of Health (1R01 HL141434 01A1)
  • National Institutes of Health (2U54HL120163)
  • National Institutes of Health (1R01AG066010)
  • American Heart Association (18SFRN34110082)
  • European Commission Grant (847770)